Purity assay is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Powder storage | Minus 20 degrees Celsius, dry, dark | Desiccant used where humidity is high |
| Solution storage | Frozen, single-use aliquots | Repeated freeze-thaw cycles increase breakdown |
| Light sensitivity | Loss of intact complex under prolonged light | Amber or opaque containers reduce exposure |
| Copper assay | ICP-MS or atomic absorption spectroscopy | Reports total copper, not the fraction bound to peptide |
| Purity assay | Reversed-phase HPLC with UV or MS detection | States whether purity refers to peptide peaks or to metal content |
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
In 1998 the BPL began sourcing its plasma from the United States due to concerns over vCJD in the UK. In 2002 the Department of Health (DoH) formed DCI Biologicals Inc to purchase US company Life Resources Inc to supply all of the BPL's plasma. BPL became an operating division within new special health authority, NHS Blood and Transplant, in 2005. This placed BPL alongside the National Blood Service and the organ transplant division, a strategic partnership to safeguard blood, tissues and blood products. On 31 December 2010 the BPL was vested into a limited company, Bio Products Laboratory Ltd, and ownership transferred to the DoH, with BPL Ltd and DCI Biologicals Inc brought under the same DoH holding company, Plasma Resources UK Ltd. On 18 July 2013 it was announced by Business Secretary Vince Cable that Bain Capital had bought 80% of Plasma Resources UK (PRUK) from the DoH for £230m, which included both BPL and DCI Biologicals. The company was subsequently renamed BPL Holdings, with the original BPL site now called BPL Therapeutics and DCI named BPL Plasma. In 2018, when it was the sole owner, the Chinese group Creat had announced that it planned to integrate BPL's operations with German plasma product manufacturer Biotest. In 2022, Creat was required to dispose of its U.S. plasma centers which necessitated a sale of BPL as a whole. The sale was made to Kedrion BioPharma and BPL became a subsidiary of the Kedrion Group.
If increased glucagon does not raise blood sugar levels to normal, the adrenal glands release epinephrine. Epinephrine works to also increase gluconeogenesis and glycogenolysis, while also decreasing the use of glucose by organs, protecting the brain's glucose supply. After hypoglycemia has been prolonged, cortisol and growth hormone are released to continue gluconeogenesis and glycogenolysis, while also preventing the use of glucose by other organs. The effects of cortisol and growth hormone are far less effective than epinephrine. In a state of hypoglycemia, the brain also signals a sense of hunger and drives the person to eat, in an attempt to increase glucose.
== Common names == Eurycoma longifolia is also known by the common names penawar pahit, penawar bias, bedara merah, bedara putih, lempedu pahit, payong ali, tongkat baginda, muntah bumi, petala bumi, bidara laut (all Malay-Indonesian); babi kurus (Javanese); cây bá bệnh (Vietnamese); tho nan (Laotian); lan-don, hae phan chan, phiak, plaa lai phuenk, tung saw (all Thai); "long jack" (US); langir siam (Bahrain). Many of the common names refer to the plant's medicinal use and extreme bitterness. Penawar pahit translates simply as "bitter charm" or "bitter medicine". Older literature, such as a 1953 article in the Journal of Ecology, may cite only penawar pahit as the plant's common Malay name. E. longifolia is known by common names "tongkat ali" and "pasak bumi" in the South East Asian region, but these names are also used for similar species, Polyalthia bullata. The bark and root of E. longifolia is more white/yellow-ish compared to the darker-colored P. bullata, which has led to the former being known as "tongkat ali/pasak bumi putih" or "tongkat ali/pasak bumi kuning", and the latter as "tongkat ali/pasak bumi hitam". ("Putih" means "white", "kuning" means "yellow", and "hitam" means "black" in Malay/Indonesian.) Indonesia also has a red-coloured variety known as "tongkat ali/pasak bumi merah" ("merah" meaning "red"), which is being studied by researchers and has not had its species classified. Eurycoma longifolia is also known by the species name Eurycoma longifolia Jack, as this was the name used by botanist William Jack in his taxonomical description published in 1822.
== Adverse effects == Dutasteride has overall been found to be well tolerated in studies of both men and women, producing minimal side effects. Adverse effects include headache and gastrointestinal discomfort. Isolated reports of menstrual changes, acne, and dizziness also exist. A small risk of sexual side effects has been documented in men taking the drug during the first few months of therapy. The FDA added a black-box warning to dutasteride in 2011 describing an increased risk of high-grade prostate cancer in those who take the drug. No direct mechanistic link between 5α-reductase inhibitors and prostate cancer has been established. This is not due to a direct link between dutasteride or other 5α-reductase inhibitors and cancer per se, but rather that those who take 5α-reductase inhibitors may have a decrease in prostate-specific antigen (PSA) levels, and therefore increases in PSA (which are an indicator of possible cancer) may be masked in those who take the drug. This is thought to delay cancer diagnosis so that patients taking 5α-reductase inhibitors present with a higher-grade tumor at the time of diagnosis. The American Urological Association advises that increased risk for patients taking these drugs leads to higher prostate cancer-specific and all-cause mortality. The AUA also advises that this effect can be alleviated with more frequent screening and lower PSA cutoffs for diagnostic biopsies in men taking dutasteride or other 5α-reductase inhibitors. Dutasteride is known to reduce the growth and prevalence of benign prostate tumors.
=== Therapeutic evaluation === Several investigations correlate the Bristol stool scale in response to medications or therapies, in fact, in one study was also used to titrate the dose more finely than one drug (colestyramine) in subjects with diarrhoea and faecal incontinence. In a randomised controlled study, the scale was used to study the response to two laxatives: Macrogol (polyethylene glycol) and psyllium (Plantago psyllium and other species of the same genus) of 126 male and female patients for a period of 2 weeks of treatment; failing to show the most rapid response and increased efficiency of the former over the latter. The primary outcomes were the number of weekly bowel movements, stool consistency according to the Bristol stool scale, time to defecation, overall effectiveness, difficulty in defecating, and stool consistency. From 2010, several studies have used the scale as a diagnostic tool validated for recognition and evaluation of response to various treatments, such as probiotics, moxicombustion, laxatives in the elderly, preparing Ayurvedic poly-phytotherapy filed TLPL/AY, psyllium, mesalazine, methylnaltrexone, and oxycodone/naloxone, or to assess the response to physical activity in athletes.
Sources: en.wikipedia.org
=== Nervous system and senses === Cnidarians are generally thought to have no brains or even central nervous systems. However, they do have integrative areas of neural tissue that could be considered some form of centralization. Most of their bodies are innervated by decentralized nerve nets that control their swimming musculature and connect with sensory structures, though each clade has slightly different structures. These sensory structures, usually called rhopalia, can generate signals in response to various types of stimuli such as light, pressure, chemical changes, and much more. Medusa usually have several of them around the margin of the bell that work together to control the motor nerve net, that directly innervates the swimming muscles. Most cnidarians also have a parallel system. In scyphozoans, this takes the form of a diffuse nerve net, which has modulatory effects on the nervous system. As well as forming the "signal cables" between sensory neurons and motoneurons, intermediate neurons in the nerve net can also form ganglia that act as local coordination centers. Communication between nerve cells can occur by chemical synapses or gap junctions in hydrozoans, though gap junctions are not present in all groups. Cnidarians have many of the same neurotransmitters as bilaterians, including chemicals such as glutamate, GABA, and glycine. Serotonin, dopamine, noradrenaline, octopamine, histamine, and acetylcholine, on the other hand, are absent.
=== Borealis === Shortly before his departure from Valve in 2016, Laidlaw led a virtual reality (VR) project on the Source 2 engine, Borealis, set on the time-travelling ship mentioned in Episode Two and Portal 2. The game would skip between the Combine's conquering of Earth before Half-Life 2 and a time set shortly after Episode Two. A minigame in which players would fish off the bow of the ship was also proposed. Laidlaw said the project ended because it was too early to be working in VR: "When people are struggling with the basic tools they need to rough out a concept, it's hard to convey any sort of vision, and it all evaporated pretty quickly."
== Classes == Different hormones can be sorted into different classes, depending on their chemical structures. Within each class of hormone, chemical structures can vary, but all members of the same class have similar physiological effects. Initial research into plant hormones identified five major classes: abscisic acid, auxins, gibberellins, cytokinins and ethylene. This list was later expanded, and brassinosteroids, jasmonates, salicylic acid, and strigolactones are now also considered major plant hormones. Additionally there are several other compounds that serve functions similar to the major hormones, but their status as bona fide hormones is still debated.
== In popular culture == A fictionalized version of the Black Dragon Society "featured in much of American popular culture". It appeared in Master Comics starting with issue 21, first published by Fawcett Comics on December 10, 1941. Initially displayed as an external threat, the Black Dragon Society was given elements of a fifth column after the attack on Pearl Harbor, which reflected the fear of subversion of American society by Japanese-Americans. In DC's All Star Comics from 1942 the Society functioned as an opponent of the Justice Society of America and were likewise presented as an example of "alleged Japanese American perfidy". Another fictionalized version of the Black Dragon Society is featured in the CBS television series Raven, where they are a ninja clan operating in Hawaii.
Sources: en.wikipedia.org
The colour depends on copper held in a specific coordination environment. When the complex dissociates or the peptide is cleaved, that environment changes and the visible absorption weakens.
Frozen solutions are generally less stable than dry powder, and repeated thawing accelerates breakdown. Storage temperature, concentration and buffer composition all shift the rate, so no single figure applies to every preparation.
Chromatography separates and quantifies peptide species but does not report metal content. A separate elemental measurement is needed to show how much copper is present.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.